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Hyperdynamic circulation as well as increased hepatic larly regarding portal pressure, has not been fully elucid-
ated yet. Therefore, mainly ET-1 will be covered in theresistance contribute to portal hypertension in cirrhosis
of the liver [1]. Hyperdynamic circulation with increased following text.
cardiac output, heart rate and plasma volume and de-
creased arterial blood pressure and systemic vasodila-
tation is pivotal for the hyperdynamic circulation. This ET Plasma Concentration and Hepatic Release in
Cirrhosishas prompted intense research of a number of endogenous
neurohumoral mediators with vasodilating properties
(NO, natriuretic peptides, glucagon, etc.) [2, 3]. In patients with cirrhosis of the liver, elevated arterial
and venous plasma concentrations of ET-1 and ET-3In recent years, however, mechanisms augmenting in-
trahepatic vascular resistance and thus contributing to have been described [2, 10–16]. Interestingly, there is an
increased hepatosplanchnic release of ET in these patientsportal hypertension have received increasing attention. In
this respect, endothelins (ET) are of particular interest (fig. 1). Release of ET-1 as well as arterial and venous
plasma concentrations were found to correlate to the[4–8].
ET are a family of 21-amino acid polypeptides with hepatic-venous-pressure gradient [13, 14]. In the liver of
cirrhotic rats, increased concentrations of ET-1 and anpotent vasoactive properties. ET-1 was first isolated in
the supernatant of vascular endothelial cells [8] but later increased ET receptor density have been described [17].
Furthermore, release of ET from isolated perfused liversynthesis of both circulating isopeptides ET-1 and ET-3
was shown in other organs such as the gastrointestinal as well as from sinusoidal endothelial cells upon stimu-
lation by TGF-b have been observed [18, 19]. These find-tract [9]. ET-1 has mainly vasoconstrictive properties
by acting on the ETA receptor on smooth muscle cells. ings raise the question which cells of the liver synthesize
ET and whether this is stimulated in liver damage orET-1 binds with lower affinity also to the ETB receptor
on endothelial cells inducing a vasodilatation by the re- cirrhosis.
lease of NO and prostacyclins. ET-1 exhibits a much
higher affinity to the ETA receptor than ET-3 whereas the
ETB receptor exhibits similar affinity for both isopeptides. ET Synthesis in Various Cell Types of the Liver
Vascular response to ET thus depends on the ratio of
different receptors which seems to vary in different vascu- Expression of ET-1 in isolated liver cells was detected
mainly in sinusoidal endothelial cells and stellate cellslar regions [for reviews, see 5–8]. The role of ET-3, particu-
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Fig. 1. ET-1 plasma concentrations in
hepatic venous samples (a) and in femoral
artery (data not shown) of patients with
cirrhosis were significantly (p=0.0001)
higher than in control sujects. In the same
patients, hepatosplanchnic release of ET-1
was increased (p=0.01) compared to
controls (b) [Data adapted from 14].
a b
Table 1. Synthesis of and receptors for ET-1 in nonparenchymal administration of an ET receptor antagonist [24]. These
and parenchymal cells of the liver data suggest a role of ET in modulating portal pressure
particularly in portal hypertension.
Synthesis
Endothelial cells ? Stellate cells 9 Kupffer cells, Hepatocytes
Receptors
ET Effects on Various Cells of the LiverStellate cells ? Endothelial cells, Kupffer cells, Hepatocytes
ET receptors have been found mainly on stellate cells
and sinusoidal endothelial cells but also on Kupffer cells
and hepatocytes (table 1) [25–27]. As shown recently, ET-and to a lesser extent in Kupffer cells (table 1); following
induced decrease of the hepatic microvascular blood flowliver injury by bile duct ligation prepro-ET-1 mRNA in-
is predominantly mediated by the contraction of stellatecreased mainly in stellate cells and to a lesser extent in
cells [26, 28–30]. Therefore, an autocrine effect of ETendothelial cells [20]. These data support the finding of
appears as an interesting pathomechanism of portal hy-ET-1 overexpression in stellate cells and sinusoidal endo-
pertension: in liver damage, increased ET synthesis fromthelial cells of human cirrhotic liver [21]. Hepatic stellate
stellate cells may induce an increase of portal pressure bycells are located in the space of Disse and surround the
contraction of these cells. Furthermore, recent evidencesinusoidal capillary composed of endothelial cells and
suggests an effect of ET on hepatic microvascular ex-Kupffer cells. This anatomic location suggests a role of
change in cirrhosis, possibly by affecting the fenestrationstellate cells in the regulation of the diameter of liver
of sinusoidal endothelial cells [31]. This might be anothersinusoids and thus of portal pressure. The data on in-
mechanism contributing to a decrease of hepatic functioncreased hepatic synthesis of ET in liver damage raise the
in cirrhosis. Finally, the increase of portal pressure uponissue of how ET affects portal pressure and whether there
Kupffer cell stimulation seems to be partly mediated bymight be endocrine or paracrine effects involved.
ET as was recently shown in isolated perfused rat liver
[32].
In summary: In conclusion, plasma concentrations ofET and Portal Pressure
ET are increased in cirrhosis which may be due to
increased hepatosplanchnic release. This could reflectET causes an increase of portal pressure in vivo as
increased hepatic synthesis of ET-1, mainly by stellatewell as in isolated perfused liver [22, 23]. In cirrhotic
and sinusoidal endothelial cells. ET increases portal pres-liver, but not in controls, portal pressure decreases upon
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